[Translated article] Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis
Authors:
- E. Serra-BaldrichESE. Serra-Baldrich
- L.F. Santamaria-BabíLSL.F. Santamaria-Babí
- J. Francisco SilvestreJSJ. Francisco Silvestre
Open Access
- 9 June 2022
- journal article
- review article
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 113 (7) , T674-T684
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- Anti‐IL‐31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in miceBritish Journal of Pharmacology, 2014
- Allergen-induced production of IL-31 by canine Th2 cells and identification of immune, skin, and neuronal target cellsVeterinary Immunology and Immunopathology, 2014
- Neural processing of itchNeuroscience, 2013
- Human IL-31 is induced by IL-4 and promotes TH2-driven inflammationJournal of Allergy and Clinical Immunology, 2013
- Homeostatic chemokine receptors and organ-specific metastasisNature Reviews Immunology, 2011
- Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitisInternational Immunology, 2010
- Complete overlap of interleukin-31 receptor A and oncostatin M receptor β in the adult dorsal root ganglia with distinct developmental expression patternsNeuroscience, 2006
- IL-31: A new link between T cells and pruritus in atopic skin inflammationJournal of Allergy and Clinical Immunology, 2006
- IL-31 is associated with cutaneous lymphocyte antigen–positive skin homing T cells in patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 2006
- Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in miceNature Immunology, 2004